Dr. Reddys Laboratories Ltd on Wednesday introduced the launch of Remdesivir, meant for therapy of COVID-19 sufferers, below a model identify ‘Redyx’ in India. According to a press launch from the drug maker, the launch is a part of the licensing settlement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the best to register, manufacture and promote Remdesivir, a possible therapy for Covid-19, in 127 international locations together with India.
Remdesivir is accredited by Drug Controller General of India (DCGI) for restricted emergency use in India for the therapy of Covid-19 sufferers hospitalized with extreme signs. “Dr Reddy’s Redyx is available in strength of 100 mg vial,” it stated.
Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana stated, “We will continue our efforts to develop products that address significant unmet needs of patients.
The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”
Latest News on Coronavirus
Latest Business News
Fight towards Coronavirus: Full protection